Charles River Expects $100 Million in Cross-Selling from WuXi Merger

Charles River Laboratories and WuXi PharmaTech said they expect their upcoming merger to produce $75 million to $100 million in additional revenues by 2013, largely through cross-selling, and $20 million in cost savings. The projections were contained in a new investor presentation. The shareholders of both companies will vote on the transaction on August 5. More details.... Stock Symbols: (NYSE: CRL) (NYSE: WX)